Corporate News
Director/PDMR Shareholding
27 April 2020
Concepta plc (AIM: CPT), the innovative UK personalised healthcare company and developer of the proprietary self-test platform ("myLotus®"), the UK's most accurate home-use fertility tracking and pregnancy testing system, announces that following Admission of the Placing Shares and Subscription Shares to trading this morning, the following new ordinary shares of 0.1p ("Ordinary Shares") have been issued to the Directors at 0.8p per Ordinary Share.
|
Name |
Number of Ordinary Shares subscribed |
Number of Ordinary Shares held post Admission |
% of Ordinary Share Capital held post Admission |
|
Penny McCormick |
1,250,000 |
1,250,000 |
0.26% |
|
Maddy Kennedy |
1,250,000 |
1,250,000 |
0.26% |
|
Lyn Rees |
1,562,500 |
1,562,500 |
0.32% |
|
Adam Reynolds |
6,250,000 |
8,084,722 |
1.65% |
All terms used above are as defined in the RNS of 8 April 2020.
|
Concepta plc |
|
|
Penny McCormick , Chief Executive Officer |
via Walbrook PR |
|
Maddy Kennedy, Chief Financial Officer |
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD) |
Tel: +44 (0)20 3368 3550 |
|
Neil Baldwin |
|
|
|
|
|
Novum Securities (Broker) |
Tel: +44 (0)20 7399 9400 |
|
Colin Rowbury |
|
|
|
|
|
Walbrook PR Ltd (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 |
|
Paul McManus |
Mob: +44(0)7980 541 893 |
Notification
and public disclosure of transactions by persons discharging
managerial responsibilities ("PDMRs") and persons closely
associated ("PCA") with them.
|
1 |
Details of the person discharging managerial
responsibilities / person closely
associated |
||||
|
a) |
Name |
Penny McCormick |
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
Chief Executive Officer |
|||
|
b) |
Initial notification /Amendment |
Initial Notification |
|||
|
3 |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor |
||||
|
a) |
Name |
CONCEPTA plc |
|||
|
b) |
LEI |
213800RBHY6LZDG13168 |
|||
|
4 |
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each
place where transactions have been
conducted |
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares
|
|||
|
|
|
||||
|
Identification code |
ISIN: GB00BYZ2R301 |
||||
|
|
|
||||
|
b) |
Nature of the transaction |
Subscription for cash |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
£0.008 |
1,250,000 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
As above |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e) |
Date of the transaction |
27 April 2020 |
|||
|
f) |
Place of the transaction |
London Stock Exchange, AIM |
|||
Notification
and public disclosure of transactions by persons discharging
managerial responsibilities ("PDMRs") and persons closely
associated ("PCA") with them.
|
1 |
Details of the person discharging managerial
responsibilities / person closely
associated |
||||
|
a) |
Name |
Maddy Kennedy |
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
Chief Financial Officer |
|||
|
b) |
Initial notification/Amendment |
Initial Notification |
|||
|
3 |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor |
||||
|
a) |
Name |
CONCEPTA plc |
|||
|
b) |
LEI |
213800RBHY6LZDG13168 |
|||
|
4 |
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each
place where transactions have been
conducted |
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares
|
|||
|
|
|
||||
|
Identification code |
ISIN: GB00BYZ2R301 |
||||
|
|
|
||||
|
b) |
Nature of the transaction |
Subscription for cash |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
£0.008 |
1,250,000 |
|
|
|
|
|
6,250,000 of these shares were acquired by the spouse of Mrs Kennedy. |
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
As above |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e) |
Date of the transaction |
27 April 2020 |
|||
|
f) |
Place of the transaction |
London Stock Exchange, AIM |
|||
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.
|
1 |
Details of the person discharging managerial
responsibilities / person closely
associated |
||||
|
a) |
Name |
Lyn Rees |
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
Non-Executive Director |
|||
|
b) |
Initial notification /Amendment |
Initial Notification |
|||
|
3 |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor |
||||
|
a) |
Name |
CONCEPTA plc |
|||
|
b) |
LEI |
213800RBHY6LZDG13168 |
|||
|
4 |
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each
place where transactions have been
conducted |
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares |
|||
|
|
|
||||
|
Identification code |
ISIN: GB00BYZ2R301 |
||||
|
|
|
||||
|
b) |
Nature of the transaction |
Subscription for cash |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
£0.008 |
1,562,500 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
As above |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e) |
Date of the transaction |
27 April 2020 |
|||
|
f) |
Place of the transaction |
London Stock Exchange, AIM |
|||
Notification
and public disclosure of transactions by persons discharging
managerial responsibilities ("PDMRs") and persons closely
associated ("PCA") with them.
|
1 |
Details of the person discharging managerial
responsibilities / person closely
associated |
||||
|
a) |
Name |
Adam Reynolds |
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
Non-Executive Chairman |
|||
|
b) |
Initial notification /Amendment |
Initial Notification |
|||
|
3 |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor |
||||
|
a) |
Name |
CONCEPTA plc |
|||
|
b) |
LEI |
213800RBHY6LZDG13168 |
|||
|
4 |
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each
place where transactions have been
conducted |
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares |
|||
|
|
|
||||
|
Identification code |
ISIN: GB00BYZ2R301 |
||||
|
|
|
||||
|
b) |
Nature of the transaction |
Subscription for cash |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
£0.008 |
6,250,000 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
As above |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e) |
Date of the transaction |
27 April 2020 |
|||
|
f) |
Place of the transaction |
London Stock Exchange, AIM |
|||
About
Concepta
PLC ( www.conceptaplc.com )
Concepta PLC is an AIM-quoted pioneering UK healthcare company that
has developed a proprietary product, myLotus®, targeted at the
personalized mobile health market with a primary focus on hormone
testing and increasing a woman's chances of naturally getting
pregnant and to provide insight to unexplained infertility.
myLotus® is currently the only consumer product which allows both
quantitative and qualitative home (self-test) test measurement of a
woman's personal luteinizing hormone (LH) during ovulation and human
chorionic gonadotropin (hCG) hormone level during pregnancy,
facilitating higher conception rates and early diagnosis of
fertility issues. The proposition of myLotus® is to
empower women to better understand their hormone levels and
menstrual cycle and help women conceive naturally by identifying
their window of fertility and optimal time for conception.
The Company has received CE-mark certification for
myLotus® and has launched its first product in the
UK. The Company is preparing plans to roll-out across the core EU
countries in 2020.
myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.